Please click on photos above for more information about how to obtain BabyBIGĀ®, consultation for suspected infant botulism, and laboratory testing in California.
Also visit our
infant botulism main page for in-depth information.
What is infant botulism? Infant botulism is an orphan ("rare") disease that affects infants āprimarily under 1 year of age. First recognized in 1976, infant botulism occurs globally and is the most common form of human botulism in the United States.
BabyBIGĀ®, Botulism Immune Globulin Intravenous (Human) (BIG-IV) is an orphan drug that consists of human-derived anti-botulism toxin antibodies that is approved by the U.S. Food and Drug Administration for the treatment of infant botulism type A and type B.